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Summary. Glutathione S-transferases (GSTs) are implicated
in cytotoxic drug resistance in leukaemia. In a previous
study, expression of mu class GST (GSTM) was associated
with poor prognosis in childhood acute lymphoblastic leuk-
aemia (ALL), however, that study did not differentiate
between individual GSTM isoforms. This study, therefore,
investigated individual GSTM isoform expression in ALL
blasts at the mRNA level. Leukaemic blasts from 21 children
with ALL were studied. Interindividual variation in the pat-
tern of GSTM mRNA isoform expression was demonstrated.
GSTM2 transcript was expressed in all patients in contra-
distinction to GSTM5, which was not detected in any sample.
GSTM3 and GSTM4 expression varied between individuals,
with GSTM3 expressed in 62% and GSTM4 in 24% of
patients. Lymphoblast expression of GSTM3 was positively
related to good prognosis whereas expression of GSTM4 was
not related to clinical outcome in this small cohort. No rela-
tionship was demonstrated with established indicators of
prognosis, including sex, age, immunophenotype and pre-
senting white cell count. The results suggest that expression
of GSTM3 may play a role in determining prognosis in
childhood ALL and could provide more information for
accurate stratification of treatment. Further studies are
required to determine whether there is a causal relationship
between GSTM3 expression and clinical outcome.
Keywords: glutathione S-transferases, mu class isoforms,
ALL, prognostic indicators, drug resistance.
Cytosolic glutathione S-transferases (GSTs) form a multi-
gene family of enzymes, currently divided into four classes,
a (GSTA), l (GSTM), p (GSTP) and h (GSTT), on the basis of
sequence homology and immunological cross-reactivity
(Mannervik et al, 1992; Tsuchida & Sato, 1992). GSTs
form an important part of intracellular detoxification
pathways. They catalyse the conjugation of glutathione
(GSH) with electrophilic compounds, including certain
groups of cytotoxic drugs and other xenobiotics. The
resulting conjugate is generally less toxic, more soluble
and more readily excreted from the cell via energy-
dependent protein pumps, including the multidrug resis-
tance protein, MRP (Jedlitschky et al, 1996). All GSTs are
highly specific with regard to GSH but their electrophile
specificity varies considerably between the classes. Further-
more, within each class, the isoforms exhibit significant
differences in substrate specificity, in spite of having
considerable sequence homology (Commandeur et al,
1995; Gulick & Fahl, 1995). For example, the human l
class isoenzyme GSTM1 can catalyse the conjugation of
GSH with trans-stilbene oxide, a capability not shared by
other GST classes or even other isoforms of the l class
family (Commandeur et al, 1995).
The level of gene product expression of the different
classes of GST varies between tissues. In human liver,
GSTA constitutes 80% of the total GST protein expressed,
of which the GSTA1-1 isoform predominates (Van
Ommen et al, 1990). In contrast, human colonic tissues
express GSTP as the major class of the GST family
(Singhal et al, 1992). Differential expression of GST
subclasses can also occur within an organ. For example,
in the kidney, GSTA predominates in the proximal
tubules, whereas GSTP and GSTM are the major isoforms
in the thin loop of Henle, distal tubules and collecting
ducts (Campbell et al, 1991).
Both GSTM1 and the h class GSTs (GSTT) exhibit
interindividual differences in expression as a consequence
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of the following genetic polymorphisms (Zhong et al,
1993). In approximately 50% of the Caucasian popula-
tion, the GSTM1 gene is deleted from both alleles on
chromosome 1 (Pemble et al, 1994). Similarly, for the
GSTT gene, which is localized to chromosome 22 (Tan
et al, 1995), a GSTT1 null genotype is described in
approximately 16% of Caucasians (Chen et al, 1996). A
number of studies have emphasized the importance of
these genetic polymorphisms in susceptibility to carcino-
genesis. For example, an increased frequency of the
GSTT1 null genotype has been described in patients with
myelodysplastic syndrome (Chen et al, 1996) and the
homozygous deletion of the GSTM1 gene is associated
with increased risk of lung carcinoma in smokers
(Ketterer et al, 1992; Nakajima et al, 1995). As yet,
however, no correlation with drug resistance has been
reported for either polymorphism.
Previous work reported by our group demonstrated a
correlation between GSTM expression and poor prognosis
in childhood ALL. In this study, we observed that
patients whose bone marrow expressed GSTM, as deter-
mined by immunohistochemistry, had a significantly
increased risk of relapse (Hall et al, 1994). The antibody
used was a polyclonal anti-GSTM antibody raised against
GSTM purified from liver extracts and, therefore, was
unable to distinguish between the isoforms within the mu
class of GSTs. In order to determine if prognosis was
related to the GSTM1 polymorphism gene, we examined
the GSTM1 genotype in the same study population but
no correlation was found between GSTM1 genotype and
clinical outcome (Matheson et al, 1997). In the absence
of any studies investigating the expression of the
remaining four GSTM isoforms in leukaemic blasts, we
chose to study the expression of the GSTM isoforms 2–5
at the mRNA level. This was performed using reverse-
transcription polymerase chain reaction (RT-PCR) to
examine the relationship between individual GSTM iso-
form expression and established indicators of prognosis in
childhood ALL.
MATERIALS AND METHODS
Patient samples analysed were derived from patients
presenting to major medical centres in the Netherlands,
Denmark or Germany. Patients were treated according to
their respective national protocols for the Dutch Childhood
Leukaemia Study Group (SNWLK), the Danish Nordic
Society of Paediatric Haematology and Oncology (NOPHO)
and the German Co-operative ALL (COALL) Study Group.
The bone marrow and blood samples were sent to the
Haematology, Oncology, Immunology (HOI) Laboratory,
Vrije University, Amsterdam, where the initial sample
preparation was performed. Leukaemic blast pellets were
prepared by Ficoll extraction and pellets of 1 · 107 cells
were stored at )80C for subsequent RNA extraction.
Total RNA extraction was performed using caesium
chloride ultracentrifugation based on the method of Chirg-
win et al (1979).
RNA preparation and reverse transcription was per-
formed using the Superscripttm preamplification system
(Gibco BRL, Paisley, UK following manufacturer’s recom-
mendations). Total RNA (0Æ1 lg) was used together with
50 pmol/l of an oligo dT primer to programme each reverse
transcription reaction. The resulting first strand cDNA was
either maintained on ice, if PCR was to be performed
immediately, or stored at )20C.
PCR was performed in a Perkin Elmer (Bucks, UK) thermal
cycler (Model 480). Each reaction mixture contained;
1 · Bioline buffer, 2Æ5 units Taq (Promega, Southampton,
UK), 200 lmol/l dNTPs, 1Æ5 mmol/l MgCl2, 2 ll cDNA and
50 pmol/l of the appropriate primer. Positive controls for
GSTM isoforms 2–4 and GADPH were prepared using cDNA
derived from a neuroblastoma cell line, SHSY1, known to
express these transcripts. No positive control for GSTM5,
however, could be obtained.
Primer sequences are shown in Table I. GADPH primers
were used as an internal standard as described by Moretti et al
(1994). Primers were synthesized using an automated DNA/
RNA synthesiser (model 292; Applied Biosystems, CA, USA).




primer sequence Primer sequence
*PCR product
size (bp)
GSTM2 HGTM2-338 5¢ GTA TGC AGC TGG CCA AAC
HP2 5¢GAG ATG AAG TCC TTC AGA TTT 235
GSTM3 HGTM3-338 5¢ GCA CAC AAC TGA TAA GGC
HGTM3–607r 5¢ TTG CAG AAC TGA TCA GAC 292
GSTM4 HGTM4-338 5¢ CCA ATC AGC TGG CCA GAG
GSTM4-E7 5¢ GGC TCA AAT ATA CGG TGG AG 193
GSTM5 HGTM5-338 5¢ACA TGG AGC TGG TCA GAC
HGTM5-E7 5¢ GGC TCA AAT ATA CGC TTC AT 196
GADPH GADPH8 5¢ CGT GTC CCC CAC TGC CAA C
GADPH9 5¢ TGT TGC TGT AGC CAA ATT CG 268
*PCR product size generated from a cDNA template.
All primers were targeted to exonic sequences. GAPDH primers were used as an internal
standard as described by Moretti et al (1994).
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The PCR profile consisted of 35 cycles of 94C for 3 min,
56C for 1 min and 72C for 30 s. The products were
electrophoresed through 2% agarose and visualized using
ethidium bromide, alongside a 123 bp marker (Gibco). PCR
products for each of the GSTM isoforms 1–5 are shown in
Fig 1. If a band of the appropriate size was visible, the
sample was designated as positive for mRNA expression (‘1’
in Table II), while if no band was visible at the expected
base-pair size, this was designated as negative (‘0’ in
Table II). The band was designated positive irrespective of
the degree of intensity. The data were analysed without
knowledge of the clinical details of the patients.
Fig 1. RT-PCR products from each primer
pair specific for GSTM isoforms 1–5. PCR
products from leukaemic blasts separated on
2% agarose gel, stained with ethidium bro-
mide and visualized under ultra-violet light to
demonstrate the products.
Table II. Lymphoblast GSTM mRNA isoform expression in childhood ALL.
Patient
Presence of RT-PCR product
M2 M3 M4 M5 GADPH
494 1 0 0 0 1
3446 1 0 1 0 1
3882 1 1 0 0 1
4093 0 1 0 0 1
4483 1 1 1 0 1
4506 1 0 0 0 1
6597 1 0 0 0 1
6920 1 1 1 0 1
7275 1 0 1 0 1
7335 1 1 0 0 1
7346 1 0 1 0 1
7376 1 1 0 0 1
7698 1 1 0 0 1
7792 1 1 0 0 1
7811 1 0 0 0 1
7821 1 1 0 0 1
7874 1 1 0 0 1
7965 1 0 0 0 1
8091 1 1 0 0 1
8096 1 1 0 0 1
8348 1 1 0 0 1
Number of patients
positive for GSTM isoform
20 13 5 0 21
% of patients positive
for GSTM isoform
95 62 24 0 100
RT-PCR products were separated by agarose gel electrophoresis and visualized
with ethidium bromide. ‘1’ designates the presence of the correct RT-PCR product.
‘0’ designates no detectable RT-PCR product. GADPH was used as a positive control
for the reverse transcription.
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The identity of PCR products was verified by restriction
fragment length polymorphisms (RFLP) using the endonuc-
leases Dde1, SfaN1 and Mbo1 (NE Biolabs, Herts, UK). PCR
products were separated by electrophoresis through 3Æ5%
Genetic Technology Grade(GTG) Nusieve agarose gels, and
the PCR bands visualized and purified (GeneluteTM) prior to
restriction endonuclease digestion. RFLP analyses for GSTM
2, 3, 4 and 5 all generated the predicted size products.
RESULTS
Ten male and 11 female patients were studied (Table III).
The mean age at presentation was 63 months, range
4–135 months. Three samples were T-lineage ALL immu-
nophenotype and 18 were B-lineage immunophenotype.
Representative results are shown in Figs 2 and 3,
demonstrating positive expression of mRNAs encoding
GSTM2, M3, M4 and GADPH. In two patients, two separate
pellets were available and were used to confirm the
reproducibility of the technique (data not shown). The
results for all the patients included in this study are shown
in Table II. GSTM2 mRNA was expressed in all but one
patient sample while that for GSTM5 was not expressed in
any of the samples included in this study. GSTM3 tran-
scripts were expressed in 13 samples (62%) and for GSTM4
in five samples (24%). In only two samples were both






494 C female 39 168
3446 null male 114 85
3882 T female 135 46
4093 preB female 25 37
4483 C male 86 49
4506 preB male 25 71
6597 C female 4 492
6920 C female 43 356
7275 preB male 49 20
7335 T male 131 371
7346 C female 64 26
7376 C male 61 81
7698 C female 68 36
7792 preB female 36 95
7811 preB male 42 10
7821 preB female 52 60
7874 C male 73 103
7965 C female 45 5
8091 C male 88 6
8096 T male 126 800
8348 preB female 28 54
*Immunophenotype: C, common ALL; N, null-type ALL; preB, early B-lineage ALL; T,
T-lineage ALL.
Peripheral blood white cell count at initial presentation.
Fig 2. Expression of GSTM isoforms in leuk-
aemic blasts. PCR products from patient 7275
separated on 2% agarose gel and visualized
with ethidium bromide. Patient 7275
expressed GSTM2, M4 and GADPH but not
GSTM3 and M5.
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GSTM3 and GSTM4 mRNA species co-expressed. The
‘housekeeping’ gene GADPH was used as a positive control
for each cDNA sample and was shown to be present in all
samples analysed.
The relationships between expression of GSTM 3 and 4 and
known indicators of prognosis in childhood ALL were
analysed. GSTM2 and GSTM5 were not considered in this
analysis as their ubiquitous presence or absence would
preclude any significant contribution to differences in clinical
outcome. The expression of GSTM3 and GSTM4 was shown
to be the same in male and female patients. Similarly, no
significant relationships were demonstrated between expres-
sion of either GSTM3 or GSTM4 transcripts and age (Mann–
Whitney U-test P ¼ 0Æ12 and 0Æ4 respectively) or white
cell count (WCC) at presentation (Mann–Whitney U-test
P ¼ 0Æ44 and 0Æ76 respectively). All of the three samples
immunophenotyped as T-lineage ALL expressed GSTM3 but
none expressed GSTM4 whereas, of those samples immuno-
phenotyped as B lineage, 10/18 (56%) expressed GSTM3 and
5/18 (28%) expressed GSTM4 (Table IV).
The availability of cytogenetic data for the patients
included in this study was limited. As historical samples
were used, it was not possible to undertake any further
molecular analysis. Therefore, any relationship between
GSTM isoform expression and cytogenetic abnormalities
could not be examined.
Survival data were available on 20 of the 21 patients
studied. The overall 5-year survival for the cohort of
patients in this study was 55% and the 5-year event-free
survival was 35% (Fig 4). Events included one patient
whose death occurred during induction therapy, while in all
other patients the events were relapses. A significantly
better overall survival was observed in patients with blasts
expressing GSTM3 mRNA [Fig 5, log-rank test 5Æ22, degrees
of freedom (d.f.) 1, P ¼ 0Æ02]. These patients also showed
better event-free survival (log-rank test 6Æ18, d.f. 1,
P ¼ 0Æ01). In contrast, clinical outcome was not influenced
by expression of the GSTM4 transcript (Fig 6).
DISCUSSION
Interindividual variation in the expression of GSTM isoforms
in leukaemic blasts was demonstrated in this cohort of
children with ALL. GSTM2 mRNA transcripts were
expressed in 95% of patients analysed whereas no patient
expressed GSTM5. The expression of GSTM3 and GSTM4
displayed the greatest interindividual variation. These two
isoform transcripts were expressed simultaneously in only
two patients (9Æ5%). GSTM3 was expressed in all of the
three T-lineage samples analysed and in 10 of 18 (56%)
B-lineage samples, whereas GSTM4 was only expressed in
five of 18 (28%) B-lineage samples and not in the T-lineage
samples. No relationships were demonstrated between the
mRNA expression of either GSTM3 or GSTM4 and other
established indicators of prognosis in childhood ALL,
including sex, age at presentation and presenting WCC.
Fig 3. Expression of GSTM isoforms in leuk-
aemic blasts. PCR products from patient 4483
separated on 2% agarose gel and visualized
with ethidium bromide. Patient 4483
expressed GST M2, M3, M4 and GADPH but
not GSTM5.





expressed not expressed expressed not expressed
n % n % n % n %
B lineage 18 10 56 8 44 5 28 13 72
T lineage 3 3 10 0 0 0 0 3 100
n, number of samples.
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GSTM3 expression was positively related to clinical
outcome, however, no relation was found between GSTM4
expression and survival. The Kaplan–Meier survival curves
generated in this study should be interpreted with caution
because the number of patients included in the study was
small and the follow-up period for many patients was short.
Nevertheless, the results of this initial analysis suggest that
further investigation of the lymphoblast expression of GSTM
isoforms with a larger number of patients could prove
valuable.
The five-year overall and event-free survival of the
patients included in this study (55% and 35% respectively)
were considerably less than currently reported survival
figures. However, there was an inherent bias in selection of
patients for this study. A large number of cells was needed
to obtain sufficient mRNA for analysis. Samples from
patients presenting with a high WCC were, therefore, more
likely to be sent for research purposes and result in a
successful RNA extraction. This was reflected in the study
cohort which included a high proportion of patients with a
high WCC at presentation; 11 from 21 patients (52%) had
a presenting WCC greater that 50 · 109/l. A high WCC is
a known predictor of poor prognosis and could account for
the poor clinical outcome of patients included in this
study.
This is the first reported study of individual GSTM isoform
expression at the mRNA level in childhood leukaemia.
Earlier studies of GSTM expression in leukaemia have used
immunologically based techniques. We previously reported
that expression of GSTM was related to an increased risk of
relapse in childhood ALL (Hall et al, 1994) but could not
differentiate between GSTM isoforms. The rabbit polyclonal
antibodies used in that study were raised against GSTM
purified from hepatic extracts, which comprise predomin-
antly of GSTM1 (Hall et al, 1994). Recently, Den Boer et al
Fig 4. Kaplan–Meier overall and event-free survival curves for
childhood ALL. Survival data were available on 20 of the 21 patients
analysed. Vertical lines represent censored patients. Five-year
overall survival was 55% and 5-year event-free survival was 35%.
Fig 5. Comparison of overall and event-free survival in children
with ALL grouped according to expression of GSTM3 in leukaemic
blasts. Event-free survival data were available on 20 of the 21
patients analysed. Vertical lines represent censored patients. Both
overall and event-free survival were significantly increased in
patients with lymphoblasts positive for GSTM3 (log-rank test 6Æ18,
d.f. 1, P ¼ 0Æ01 and log-rank test 5Æ22, d.f. 1, P ¼ 0Æ02 respect-
ively).
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(1999) examined GST expression in childhood leukaemia by
flow cytometry using the same antibodies. They also found
no relationship between GSTM expression and known
indicators of prognosis, however, the follow-up period on
their patients was too short to yield survival data. Again,
the technique used by Den Boer et al (1999) could not
differentiate between individual GSTM isoforms. Campbell
et al (1991) reported that antisera raised against GSTM1 or
GSTM2 did not cross-react with GSTM3. It is, therefore,
probable that in our previous studies, the immunopositivity
reflected either GSTM1 or M2 expression rather than
expression of the other GSTM isoforms.
It is known that GST expression is tissue-type specific, as
is the expression of each of the GSTM isoforms (Campbell
et al, 1991; Ramjee et al, 1994; Rowe et al, 1997).
Furthermore, interindividual variation in GSTM1 expres-
sion, as a result of genetic polymorphism, is well known
Approximately 40–60% of the population are homozygous
to the GSTM1 null gene (Bell et al, 1992; Ketterer et al,
1992). More recently, allelic variation in the GSTM3 gene
has been reported but, unlike GSTM1, this is not due to a
null allele but results from a 3 bp deletion in intron 6
(Inskip et al, 1995). Studies examining the association
between GSTM3 polymorphism and the risk of lung and
colorectal cancer suggest the incidence of the GSTM3 allelic
variant to be around 20% in the normal population
(Loktionov et al, 2001; Risch et al, 2001). Interindividual
differences in expression of GSTM4 in a given tissue type
have not been previously reported. Moreover, although
GSTM3 polymorphism has been studied in the context of
cancer susceptibility, it has not been studied in the context
of leukaemia and there no are previous studies examining
the influence of GSTM3 expression on response to treat-
ment.
The mechanism by which expression of GSTM3 might
convey a survival advantage in childhood ALL is presently
unclear and warrants further investigation. GSTs are
usually described as detoxifying enzymes, therefore, over-
expression of an isoform would not be expected, a priori, to
lead to increased cytotoxicity of a drug. Cytotoxic GST
conjugates have been described (Pickett & Lu, 1989;
Gulick & Fahl, 1995) but the conjugates were of
halogenated hydrocarbons rather than the cytotoxic drugs
used in the treatment of leukaemia. There is considerable
evidence that the GSTM3 protein is the most distantly
related member of the GSTM family. The protein encoded
by the GSTM3 gene shares only 70% homology with other
GSTM isoforms, and has atypical catalytic and structural
properties, differing significantly from other GSTs. The
GSTM 1–5 gene cluster has been mapped to human
chromosome 1p13 (Pearson et al, 1993; Gough et al,
1994). A physical map of the five l class genes demon-
strated that four of these are orientated in a head to
tail array, 5¢-M4-M2-M1-M5-3¢ (Xu et al, 1998). More
recently, the GSTM3 gene was identified as having an
inverted orientation, situated downstream from GSTM5 in
a 5¢-M5 3¢-3¢-M3 5¢ orientation (Patskovsky et al, 1999).
A greater knowledge of the physicochemical properties of
human GSTM3 and the factors regulating its expression
are required before any mechanism of enhancing survival
in childhood leukaemia can be postulated.
It is possible that expression of GSTM3 itself does not
directly contribute to the mechanism for a good treatment
response but is simply a marker of altered expression of an
unrelated gene. It is interesting to note that chromosome 1
is frequently involved in recurrent gene rearrangements in
ALL (Nourse et al, 1990), however, breakpoint loci in the
vicinity of the GSTM gene cluster have not yet been
reported.
Improvement in the outlook for children with acute
leukaemia might be achieved by directing more intensive
therapy to ‘high-risk’ disease. For patients predicted to have
a good prognosis, less intensive treatment may reduce
both short- and long-term morbidity without an increase in
mortality. This approach assumes that patients with
resistant disease can be accurately identified. WCC, immu-
nophenotype, and cytogenetics. Furthermore, in a current
Fig 6. Comparison of overall and event-free survival in children
with ALL grouped according to expression of GSTM4 in leukaemic
blasts. Survival data were available on 20 of the 21 patients
analysed. Vertical lines represent censored patients. There was no
significant difference between GSTM4-positive and -negative
lymphoblasts for overall survival (log-rank test 0Æ01, d.f. 1,
P ¼ 0Æ92) and event-free survival (log-rank test 0Æ11, d.f. 1,
P ¼ 0Æ74).
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Dutch–German collaboration, in vitro drug sensitivity data
are being used to stratify patients. However, a recent
prospective study analysing the predictive values of the
traditionally accepted indicators of prognosis found the
prognostic information was contained in four variables: age,
sex, WCC and cytogenetic features (Donadieu et al, 1998).
The predictive power of each variable was low and it was
suggested that each factor accounted for no more than 4%
of the overall variability in prognosis. To date, there appears
to be no single determinant of resistant disease in childhood
leukaemia. Our results suggest that mRNA expression of
GSTM3 was associated with good prognosis, however,
further studies are indicated. This study was limited by
the selection bias in the cohort towards patients with high
WCC. Further studies involving a greater number of
patients would be required to establish the true predictive
power of GSTM3 expression in childhood ALL. If expression
of GSTM3 proves to have a direct role in determining
clinical outcome in childhood ALL, it may be possible to
exploit this observation in the development of novel
therapeutic agents.
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